Weekly high-dose liposomal amphotericin B for secondary prophylaxis of invasive fungal disease in immunocompromised children: experience from a pediatric case series

about

Weekly high-dose liposomal amphotericin B for secondary prophylaxis of invasive fungal disease in immunocompromised children: experience from a pediatric case series

Item

http://www.wikidata.org/entity/Q54265693

description

im August 2012 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 01 August 2012

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2012

@uk

name

Weekly high-dose liposomal amp ...... e from a pediatric case series

@en

Weekly high-dose liposomal amp ...... e from a pediatric case series

@nl

type

Item

label

Weekly high-dose liposomal amp ...... e from a pediatric case series

@en

Weekly high-dose liposomal amp ...... e from a pediatric case series

@nl

prefLabel

Weekly high-dose liposomal amp ...... e from a pediatric case series

@en

Weekly high-dose liposomal amp ...... e from a pediatric case series

@nl

P1476

Weekly high-dose liposomal amp ...... e from a pediatric case series

@en

P2093

Cristina Moroni

http://www.w3.org/2001/XMLSchema#string

Elio Castagnola

http://www.w3.org/2001/XMLSchema#string

Francesca Fioredda

http://www.w3.org/2001/XMLSchema#string

Francesca Ginocchio

http://www.w3.org/2001/XMLSchema#string

Ilaria Caviglia

http://www.w3.org/2001/XMLSchema#string

Maura Faraci

http://www.w3.org/2001/XMLSchema#string

Paola Barabino

http://www.w3.org/2001/XMLSchema#string

P2860

Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

Voriconazole pharmacokinetics and pharmacodynamics in children.

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.

Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update.

P304

243-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/1973947812Y.0000000012

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Riccardo Haupt

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23040693

http://www.w3.org/2001/XMLSchema#string